A Delaware federal judge correctly found Bard’s patents invalid since the company failed to show its asserted claims represented a meaningful advance over port products that predated them, the appeals court ruled Monday.
The earlier ports and the Bard patents both described a feature where the implants could be detected under a patient’s skin using an x-ray device, according to the unsigned opinion. The patents’ differentiator—a description of a port device with specific radiographic ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.